Vyzkoušejte nový nástroj s podporou AI
Summon Research Assistant
BETA
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Blauvelt, Andrew, Papp, Kim A., Griffiths, Christopher E.M., Randazzo, Bruce, Wasfi, Yasmine, Shen, Yaung-Kaung, Li, Shu, Kimball, Alexa B.
Published in Journal of the American Academy of Dermatology (01.03.2017)
Published in Journal of the American Academy of Dermatology (01.03.2017)
Get full text
Journal Article
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Reich, Kristian, Armstrong, April W., Foley, Peter, Song, Michael, Wasfi, Yasmine, Randazzo, Bruce, Li, Shu, Shen, Y.-K., Gordon, Kenneth B.
Published in Journal of the American Academy of Dermatology (01.03.2017)
Published in Journal of the American Academy of Dermatology (01.03.2017)
Get full text
Journal Article
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Papp, Kim, Bachelez, Herve, Costanzo, Antonio, Foley, Peter, Gooderham, Melinda, Kaur, Primal, Narbutt, Joanna, Philipp, Sandra, Spelman, Lynda, Weglowska, Jolanta, Zhang, Nan, Strober, Bruce
Published in Journal of the American Academy of Dermatology (01.06.2017)
Published in Journal of the American Academy of Dermatology (01.06.2017)
Get full text
Journal Article